about
Beneficial effects of estrogen in a mouse model of cerebrovascular insufficiencyFunctional characterization of rat plasma membrane monoamine transporter in the blood-brain and blood-cerebrospinal fluid barriersFunctional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s)Quantitative Targeted Absolute Proteomics for 28 Transporters in Brush-Border and Basolateral Membrane Fractions of Rat KidneyConditionally immortalized retinal capillary endothelial cell lines (TR-iBRB) expressing differentiated endothelial cell functions derived from a transgenic rat.Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: an overview of biology and methodology.New aspects of the blood-brain barrier transporters; its physiological roles in the central nervous system.Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor.1α,25-Dihydroxyvitamin D3 enhances cerebral clearance of human amyloid-β peptide(1-40) from mouse brain across the blood-brain barrier.GAGA mediates the enhancer blocking activity of the eve promoter in the Drosophila embryo.New approaches to in vitro models of blood-brain barrier drug transport.A new in vitro model for blood-cerebrospinal fluid barrier transport studies: an immortalized choroid plexus epithelial cell line derived from the tsA58 SV40 large T-antigen gene transgenic rat.Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based ProteomicsScrambled Internal Standard Method for High-Throughput Protein Quantification by Matrix-Assisted Laser Desorption Ionization Tandem Mass Spectrometry.Depletion of vitamin E increases amyloid beta accumulation by decreasing its clearances from brain and blood in a mouse model of Alzheimer disease.Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects.Quantitative targeted proteomics for understanding the blood-brain barrier: towards pharmacoproteomics.Multi-laboratory assessment of reproducibility, qualitative and quantitative performance of SWATH-mass spectrometry.All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase.Actin filament-associated protein 1 (AFAP-1) is a key mediator in inflammatory signaling-induced rapid attenuation of intrinsic P-gp function in human brain capillary endothelial cells.The blood-brain barrier fatty acid transport protein 1 (FATP1/SLC27A1) supplies docosahexaenoic acid to the brain, and insulin facilitates transport.Major involvement of Na(+) -dependent multivitamin transporter (SLC5A6/SMVT) in uptake of biotin and pantothenic acid by human brain capillary endothelial cells.Contribution of pannexin 1 and connexin 43 hemichannels to extracellular calcium-dependent transport dynamics in human blood-brain barrier endothelial cells.Identification of transporters associated with Etoposide sensitivity of stomach cancer cell lines and methotrexate sensitivity of breast cancer cell lines by quantitative targeted absolute proteomics.Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans.Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.Attenuation of prostaglandin E2 elimination across the mouse blood-brain barrier in lipopolysaccharide-induced inflammation and additive inhibitory effect of cefmetazole.6-Mercaptopurine transport by equilibrative nucleoside transporters in conditionally immortalized rat syncytiotrophoblast cell lines TR-TBTs.Amyloid-β peptide(1-40) elimination from cerebrospinal fluid involves low-density lipoprotein receptor-related protein 1 at the blood-cerebrospinal fluid barrier.Peripheral nerve pericytes modify the blood-nerve barrier function and tight junctional molecules through the secretion of various soluble factors.Atrial natriuretic peptide is eliminated from the brain by natriuretic peptide receptor-C-mediated brain-to-blood efflux transport at the blood-brain barrierAbsolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes.Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function.The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells.Peripheral nerve pericytes originating from the blood-nerve barrier expresses tight junctional molecules and transporters as barrier-forming cells.ATP-binding cassette transporter A1 (ABCA1) deficiency does not attenuate the brain-to-blood efflux transport of human amyloid-beta peptide (1-40) at the blood-brain barrier.Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter.Expression of nuclear receptor mRNA and liver X receptor-mediated regulation of ABC transporter A1 at rat blood-brain barrier.Cerebral clearance of human amyloid-beta peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes.Function and regulation of taurine transport at the inner blood-retinal barrier.
P50
Q27349876-6E94B026-4F37-47F1-8FEE-F68BD0979FDAQ28565238-CB2B31C6-1439-4094-824A-A26B8D160970Q28569107-05629094-2D7B-40B8-9045-BCA502B0D55AQ28583547-4F06C144-41F5-425E-B935-FFC038CE6BE4Q31849254-F3334F3B-050E-441E-935C-7608E76BA7B7Q33569302-DCEC4427-0DE4-45B2-A866-C0D0316E6292Q33982108-5B8696F1-5E15-4871-B415-6124BD61B512Q34633290-66FD31D8-95BD-486B-A8EC-B8D711A1D618Q35183393-345F8F7C-F708-48B4-B39C-C237E6C1A8F4Q35211114-BEAEC579-5D34-44C7-91B3-9544FF4EC772Q35557433-34C64093-A5DE-4922-BA8F-CAE802220868Q35894214-CAC1766B-C169-4917-BA2F-5F7C76F3CC0FQ36118351-3C9F3286-8FD2-4F5B-96A4-74BCCC8004C3Q36314149-5958C4C5-9502-441A-A9D3-8192D20B08CAQ37446178-0F0CB3DB-44D8-46BE-AFAC-15C856CF08BBQ37874209-4FE49C07-B3BE-42DE-B437-FA5368D6E571Q38202164-C1675A52-18B8-485A-984F-952831419176Q38615341-DCB2FE62-4912-434F-A06D-9ADDF6EAB2DAQ38715777-CD332A8D-C688-45C3-8DEF-D332484B55A7Q38719997-3D6698DF-7FA5-479D-B855-B061F2FDE2D0Q38723657-A65F42D5-7DCF-4364-A288-C502ACEEA8F5Q38895031-34A4D309-0E49-4A97-834F-8337419A2986Q38910876-0B3AD9E9-A5AC-4ADE-9688-2FD4E782773CQ39235477-2C6CBE6C-110B-4645-AC95-B20420DEE4F7Q39249570-F5F7BFB5-D5A6-402D-87F3-454EF1AE14EDQ39379544-39258219-3792-4745-9E75-534103D5B347Q39391217-254ABB26-EE83-444D-97AD-44C98FAB90FBQ39540538-937B484A-20E4-4237-84BD-3E9F5E997074Q39541066-D3FBE71B-4688-4DF0-AB76-30629152E2F6Q39674615-E45642EB-4377-4343-AC33-26E6E9DDCC8CQ39680534-0C4EFA26-C762-4A6D-9D55-B7851A6F1A23Q39699976-144DAF75-8635-4C9A-8B11-BA6777CB45B4Q39705355-2F66C555-8DB0-47DF-A138-AF695E83B60BQ39926929-C100D8E1-2F7A-4B96-94AE-8244B6AD6008Q39973637-9DE868DF-3424-4EC2-B99D-79727E5A4329Q40024125-8CAAD2AE-0CDF-45F2-93BC-40BA76487E18Q40067280-85673A28-F412-4185-AB00-89745CD687E8Q40071369-88CB3054-5C0C-4064-8AA2-0909AF87A18DQ40073861-6F23097B-6169-489E-AB2D-59734A33D9AEQ40202470-377BACE0-DF22-4615-A19E-93097D83DD7B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sumio Ohtsuki
@ast
Sumio Ohtsuki
@en
Sumio Ohtsuki
@es
Sumio Ohtsuki
@nl
Sumio Ohtsuki
@sl
type
label
Sumio Ohtsuki
@ast
Sumio Ohtsuki
@en
Sumio Ohtsuki
@es
Sumio Ohtsuki
@nl
Sumio Ohtsuki
@sl
prefLabel
Sumio Ohtsuki
@ast
Sumio Ohtsuki
@en
Sumio Ohtsuki
@es
Sumio Ohtsuki
@nl
Sumio Ohtsuki
@sl
P1053
S-4360-2016
P106
P1153
7005580686
P31
P3829
P3835
sumio-ohtsuki
P496
0000-0003-4634-7133